Today genetic testing company 23andMe announced a $60 million deal with pharmaceutical giant Genentech to identify new drug targets and therapies, including for Parkinsonís disease (PD).
Genentech is paying for genomic sequencing for 3,000 Parkinsonís patients or first degree relatives in the robust 23andMe Parkinsonís Community. The genome is oneís complete set of DNA and could be the source of new insight into the onset and progression of Parkinsonís.
Weíll share more when the sequencing study is actively recruiting. Read more today from Matt Herper on Forbes.com.